NEW YORK – Bioinformatics company Allelica said Wednesday that it is collaborating with Thermo Fisher Scientific to combine its polygenic risk score (PRS) software with Thermo Fisher's Axiom human genotyping microarrays.
The collaboration will deliver a completed, research-use-only workflow for PRS creation and implementation, from sample prep and microarrays to risk interpretation reports.
Financial details of the collaboration were not provided.
"Providing PRS tools to deliver disease risk profiles will enable significant advances in precision medicine, including development of personalized treatment strategies for patients," Giordano Bottà, CEO and cofounder of Allelica, said in a statement.
"By integrating Allelica's software with our microarray platform, we can help solve a pain point for researchers so they can focus on translating genetic insights into impactful actions," added Kevin Lowitz, VP and general manager for microarrays at Thermo Fisher.
Thermo Fisher recently launched the Axiom PangenomiX Array for population-wide disease and pharmacogenomics research.
Allelica has been working with numerous companies to develop and implement disease-specific PRS across diverse populations. Last year, the New York City-based company partnered with Taiwanese precision medicine firm SP BioMed to determine the best genotyping technology for developing a PRS for breast cancer.
The firm has also partnered with the University of Alabama at Birmingham Cardiogenomics Clinic to study the real-world value of PRS in helping prevent coronary artery disease.